AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 400.87% | -47.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 400.87% | -47.58% | |||
| Cost of Revenue | -8.97% | 40.33% | |||
| Gross Profit | 88.63% | -108.20% | |||
| SG&A Expenses | -31.01% | 13.52% | |||
| Depreciation & Amortization | 16.70% | -4.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.84% | 27.85% | |||
| Operating Income | 62.53% | -53.83% | |||
| Income Before Tax | 71.65% | -89.21% | |||
| Income Tax Expenses | 9.40% | -620.41% | |||
| Earnings from Continuing Operations | 84.34% | -64.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 84.34% | -64.48% | |||
| EBIT | 62.53% | -53.83% | |||
| EBITDA | 68.38% | -61.02% | |||
| EPS Basic | 84.41% | -64.32% | |||
| Normalized Basic EPS | 70.31% | -88.96% | |||
| EPS Diluted | 84.09% | -59.25% | |||
| Normalized Diluted EPS | 70.31% | -88.96% | |||
| Average Basic Shares Outstanding | 0.29% | 0.12% | |||
| Average Diluted Shares Outstanding | 0.29% | 0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||